What do patients expect from erectile dysfunction therapy?

被引:25
|
作者
Hackett, GI [1 ]
机构
[1] Good Hope Hosp, Lichfield WS14 9JR, Staffs, England
关键词
apomorphine; erectile dysfunction; intracavernosal injection therapy; male sexuality; phosphodiesterase type 5 inhibitors; treatment outcome;
D O I
10.1016/S1569-9056(02)00112-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Erectile insufficiency can precipitate emotional distress and a negative spiral of events and feelings. Excessive focus by the patient on the penis as the dysfunctional unit may be associated with physical and psychological problems in the female partner. With the advent of effective, well-tolerated treatments for erectile dysfunction, including the phosphodiesterase type 5 (PDE5) inhibitor sildenafil citrate, the needs and expectations of patients and their partners concerning their medications, their physicians and other factors have come into focus. In addition to the effectiveness or tolerability of a medication, a number of nonmedical outcomes may influence patients and their partners when choosing between therapeutic modalities or pharmacotherapies. These include the spontaneity and naturalness of the sexual encounter, as well as the treatment's acceptability to the sexual partner, onset/duration of action and potential interactions with food or alcohol. Patients of different ages, marital statuses or cultures may assign distinct values to each of these criteria. Couples should therefore be involved in formulating treatment plans and afforded wide latitude when initially selecting therapy and/or deciding how, or whether, to take medications. For the. physician, erectile dysfunction represents an opportunity to diagnose and treat other comorbid diseases, including hypertension, ischemic heart disease and diabetes. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:4 / 11
页数:8
相关论文
共 50 条
  • [1] What Is the Future of Erectile Dysfunction Therapy?
    Campbell J.D.
    Milenkovic U.
    Albersen M.
    Bivalacqua T.J.
    Current Sexual Health Reports, 2018, 10 (3) : 169 - 176
  • [2] Gene therapy for erectile dysfunction: What is the future?
    Melman A.
    Davies K.
    Current Urology Reports, 2010, 11 (6) : 421 - 426
  • [3] Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)?
    T Klotz
    M Mathers
    R Klotz
    F Sommer
    International Journal of Impotence Research, 2005, 17 : 2 - 4
  • [4] Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)?
    Klotz, T
    Mathers, M
    Klotz, R
    Sommer, F
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (01) : 2 - 4
  • [5] SHOCK WAVE THERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION
    Vassilev, Vassil
    Stoilov, Dimitar
    Yotovski, Valentin
    Krastanov, Aleksandar
    Milushev, Metodi
    Yanev, Krassimir
    Georgiev, Marincho
    Dimitrov, Plamen
    Lillyanov, Ivan
    Ivanov, Georgi
    Kolev, Nikolai
    Stoykov, Boyan
    COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES, 2023, 76 (02): : 316 - 324
  • [6] Combination therapy for erectile dysfunction: Where we are and what’s in the future
    Nehra A.
    Kulaksizoglu H.
    Current Urology Reports, 2002, 3 (6) : 467 - 470
  • [7] Intracavernosal injection therapy and surgical therapy in diabetic patients with erectile dysfunction
    Savoca, G
    Silvestre, G
    Belgrano, E
    DIABETES NUTRITION & METABOLISM, 2002, 15 (01) : 53 - 57
  • [8] Preservation of erectile function and radical prostatectomy : what to expect in 2005?
    Kanso, C
    Amar, E
    Bondil, P
    Boccon-Gibod, L
    Delmas, V
    PROGRES EN UROLOGIE, 2005, 15 (04): : 621 - 625
  • [9] Therapy for erectile dysfunction in 2005
    Porst, H
    UROLOGE A, 2003, 42 (10): : 1330 - +
  • [10] Gene therapy for erectile dysfunction
    Kendirci, M
    Gur, S
    Sikka, SC
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 2758 - 2769